Operational Costs Compared: SG&A Analysis of Intra-Cellular Therapies, Inc. and Wave Life Sciences Ltd.

A Decade of SG&A: Intra-Cellular Therapies vs. Wave Life Sciences

In the ever-evolving landscape of biotechnology, operational efficiency is paramount. Over the past decade, Intra-Cellular Therapies, Inc. and Wave Life Sciences Ltd. have showcased contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Intra-Cellular Therapies saw a staggering increase of nearly 3,900% in SG&A expenses, peaking at approximately $410 million in 2023. This reflects their aggressive expansion and investment in operational capabilities. In contrast, Wave Life Sciences maintained a more conservative growth, with SG&A expenses rising by about 1,600% to $51 million in the same period. This divergence highlights differing strategic priorities: while Intra-Cellular focuses on scaling rapidly, Wave Life Sciences opts for a more measured approach. As the biotech sector continues to grow, these companies' strategies offer valuable insights into managing operational costs effectively.